BPC-157 Repair Relay Research

BPC-157: The Repair Relay

BPC-157 is a chain of 15 amino acids, first described in 1993 by a pharmacology group in Zagreb as a fragment of a larger protein in gastric juice. Three decades of rat and cell studies later, it's one of the most talked-about peptides in tendon and blood-vessel research, and one of the least studied in people. Here's where it came from, what the experiments actually measured, who ran them, and how a batch is tested.

A Fragment From Gastric Juice

BPC-157 started as a question about how the stomach protects itself, and only later became a tendon story.

In the early 1990s, Predrag Sikirić's group at the University of Zagreb was studying how the stomach holds up under stress. They described a protein in gastric juice that they named body protection compound, or BPC [1]. In 1993 they reported a 15-amino-acid piece of it that seemed to carry the activity on its own, and gave it a lab code: BPC 157 [2].

The first experiments were in the stomach. In rats, BPC 157 was compared with standard ulcer drugs across three different lesion models, and the authors reported protection in all three [3]. Later papers describe the source as human gastric juice [5], and many call it a "stable gastric pentadecapeptide", pentadeca meaning fifteen [10].

From the stomach, the research spread outwards to tendons, ligaments, muscle, blood vessels and skin wounds, almost all of it in rats [9]. That reach, and the attention BPC-157 now gets outside the lab, is why who ran the studies and what they were done in matter as much as what they found.

15 amino acidsGEPPPGKPADDAGLV Molecular weight 1419.5C62H98N16O22 First described in 1993Sikirić et al., University of Zagreb Also calledBepecin, PL 14736, PLD-116 PubChem CID 9941957CAS 137525-51-0

The Repair Relay

Tendon repair is a relay: the tissue tears, cells arrive, blood supply follows, and new collagen closes the gap. BPC-157 has been studied at each handover. Each panel pairs one leg of the relay with the experiments that looked at it.

Inside a torn tendon: wavy blue collagen fibres sweep in from both sides and fray into fine loose filaments around a dark gap, with slim tendon cells between the fibres and a capillary in the lower right.

A tear in the rope

A tendon is built like a rope: long collagen fibres packed side by side, with slim tendon cells tucked between them. When it tears, the fibres snap and fray, and a gap opens that has to be filled from scratch. Tendons are slow at this, because they carry little blood and few cells. That gap is where BPC-157's tendon research begins.

  • Collagen fibres
  • Tendon cells
  • Capillary

General tendon biology. This panel sets the scene; no BPC-157 result is shown here.

The same tear with slender glowing tendon cells leaving the fibre bundles and crawling into the gap, the brightest one furthest in.

Cells move in

Nothing can be rebuilt until cells reach the gap. In 2011, a team at Chang Gung University in Taiwan cultured pieces of rat Achilles tendon with BPC-157. More cells grew out of the tissue, more of them survived a chemical stress test, and they spread and migrated further. What didn't change is just as telling: the cells didn't multiply any faster. The peptide seemed to help them move, not divide. A 2014 follow-up found the same cells carrying more growth hormone receptors.

  • Migrating tendon cells
  • Collagen fibres

Studies: Chang et al., 2011 · Chang et al., 2014

The same tear with a new rose-coloured vessel branch growing up from the capillary toward the gap, led by a glowing warm tip cell with fine projections.

A new vessel sprouts

Repair runs on supply lines. New blood vessels branch off existing ones, led by a tip cell that feels its way forward with fine projections. In chick embryo membranes and in cultured vessel-lining cells, BPC-157 increased new vessel formation, and in rats with blocked leg circulation, blood flow returned faster. The 2017 study traced the signal to VEGFR2, a key receptor on vessel-lining cells. A 2020 study from the same group found it widened isolated rat aorta through nitric oxide.

  • Tip cell
  • New vessel and capillary
  • Tendon cells in the gap

Studies: Hsieh et al., 2017 · Hsieh et al., 2020

The same tendon repaired: thick continuous blue collagen bundles run across where the gap was, slightly brighter in the middle, with calm tendon cells and the new vessel running into the repaired section.

The gap bridged

In 2003, the Zagreb group cut the Achilles tendon in rats and followed the repair for two weeks. Compared with untreated animals, those given BPC-157 did better on strength testing, on a walking-function score and under the microscope, and the defect was smaller. The authors described full tendon integrity returning. That is a rat result from the peptide's own discoverers, and it hasn't been tested in people.

  • Repaired collagen
  • Tendon cells
  • Settled vessel

Studies: Staresinic et al., 2003

The illustrations are artistic schematics drawn from the cited studies, not microscope images. The study results come from rat tissue and cultured cells.

Who Has Studied It

A finding is stronger when someone else can repeat it. For BPC-157, that list is short.

University of Zagreb, Croatia

Sikirić and colleagues, who first described the peptide

The great majority of the published work: stomach, liver, tendon, muscle, vessel and wound models, almost all in rats. Their reviews summarise three decades of it.

1992 · 1993 · 2003 · 2021

Chang Gung University, Taiwan

One independent laboratory

Cell and tissue experiments: tendon cells in culture, growth hormone receptors, new vessel growth and vessel tone, plus a rat circulation model. Different country, different methods, results pointing the same way.

2011 · 2014 · 2017 · 2020

Air Force Medical University, Xi'an, China

Pharmacology, not healing

How rats and dogs handle the peptide: how quickly it is broken down, where it goes and how it is cleared.

2022

Outside reviewers

Loughborough (UK) and a US sports-medicine team

No new experiments. They weighed the existing studies and concluded the work is mostly in animals and has not been confirmed in people.

2019 · 2025

Most of what is known about BPC-157 comes from the laboratory that discovered it. One separate group, in Taiwan, has since reported similar effects in tendon cells and blood vessels, which makes the core findings harder to dismiss. But one independent laboratory is a thin base, and nearly every result comes from rats or cells in a dish. Outside reviewers put it plainly: the effects have yet to be confirmed in humans [9].

How Much of It Is in People?

Very little. This is the most important number on the page.

35 studies in animals or cells1 study in people, a look back at 12 patientsStudies included in a 2025 systematic review of BPC-157 in orthopaedics and sports medicine [13]

In 2025, a sports-medicine team searched three decades of literature and kept 36 studies. Thirty-five were in animals or cells. One looked back at 12 patients with knee pain. The reviewers found no clinical data establishing how BPC-157 behaves in people, and flagged the risks of unregulated manufacturing [13].

Beyond that review, the human record is thin. Its developers reported phase 2 trials in inflammatory bowel disease under the code PL 14736 [4] [12], but no results were ever published. A 2015 phase 1 registration lists no results [15]. A 2025 pilot measured blood markers and vital signs in two people before and after exposure and reported no measurable changes, with the authors calling for further studies [14]. Newer trials have been registered since, and none has reported.

Three Decades in Brief

  1. 1992

    First indexed paper on "body protection compound" (BPC), a protein the Zagreb group found in gastric juice, measured in rats under stress. [1]

  2. 1993

    The group describes BPC 157, a 15-amino-acid fragment they believed carried the protein's activity. [2]

  3. 1994

    BPC 157 is compared with standard stomach drugs across three rat ulcer models. [3]

  4. 2003

    Rat Achilles tendon study; the paper also notes trials in inflammatory bowel disease under the codes PL 14736 and PLD-116. [4]

  5. 2011

    An independent team in Taiwan reports tendon cells growing out, surviving and migrating more in culture. [5]

  6. 2017

    The same Taiwanese group links BPC-157 to new vessel growth through VEGFR2. [7]

  7. 2019

    A UK review notes the evidence is mostly in rodents, from a handful of research groups. [9]

  8. 2022

    A rat and dog study maps how the peptide is broken down and cleared. [11]

  9. 2025

    A systematic review counts 35 preclinical studies and one small clinical series in orthopaedics. [13]

  10. 2026

    BPC-157 is named on WADA's Prohibited List and in a Health Canada advisory on unauthorized peptides. [16] [17]

Where It Stands

No regulator has approved BPC-157 as a medicine, and sport bans it outright.

Sport

The World Anti-Doping Agency lists BPC-157 by name under S0, Non-Approved Substances, prohibited at all times, in and out of competition.

WADA Prohibited List, 2026

Health Canada

No BPC-157 product is authorized. An April 2026 advisory named BPC-157 among unauthorized peptides seized from online sellers, and said "research use only" labels don't exempt a product from the rules.

Health Canada, 2026

United States

BPC-157 was nominated for use by compounding pharmacies; that nomination now sits on the FDA's withdrawn list. The FDA says there isn't enough information to know whether it would cause harm. FDA staff recommended against adding BPC-157 to the list of bulk substances pharmacies may compound with. At its July 2026 meeting, the advisory committee recommended adding it anyway. The recommendation isn't binding, and the FDA hasn't made a final decision.

FDA · FDA briefing, July 2026 · Committee vote, July 2026

Reading a BPC-157 COA

A research guide is only as good as the material on the bench. These are the results that tell you what's in the vial.

Identity

Mass spectrometry confirms the 15-amino-acid chain at about 1419.5 Da, the mass of the correct sequence.

Purity

HPLC separates the sample and reports what share of the peptide signal is BPC-157 rather than synthesis by-products.

Net peptide content

How much of the powder is actually peptide, rather than water and salts, which is what sets the real amount in the vial.

Endotoxin

The LAL test measures bacterial endotoxin, a contaminant that can skew cell-based experiments.

Precision Synthetics Canada BPC-157 10 mg research vial on a dark wooden surface between iron weight plates and a heavy chain

BPC-157 10 mg

The same 15-amino-acid sequence these studies used, supplied as a freeze-dried 10 mg research vial. Our current lot is tested by SideChain Analytics, our primary laboratory in Canada, and the report can be verified directly with the lab.

Match the batch number on the vial to the report on our COA page.

View BPC-157 10 mg

Common BPC-157 Research Questions

What is BPC-157?

BPC-157 is a synthetic peptide of 15 amino acids (GEPPPGKPADDAGLV), a fragment of a larger protein described in gastric juice by a University of Zagreb group in the early 1990s. It has been studied mainly in rat models and cultured cells. [2] [19]

What does the name mean?

BPC stands for body protection compound, the name the Zagreb group gave the parent protein; 157 is the fragment's lab code. It has also been called Bepecin, PL 14736 and PLD-116 during development. [1] [4]

What did the tendon studies measure?

In cultured rat tendon tissue: how many cells grew out, how many survived a chemical stress and how far they migrated, plus growth hormone receptor levels. In rats with a cut Achilles tendon: strength on load testing, a walking-function score, the size of the defect and the tissue under the microscope. [4] [5] [6]

What did the blood-vessel studies measure?

New vessel formation in chick embryo membranes and in cultured vessel-lining cells, blood-flow recovery in a rat model of blocked leg circulation, VEGFR2 signalling, and how isolated rat aorta relaxed through nitric oxide. [7] [8]

How much research has been done in people?

Very little. A 2025 systematic review found 35 preclinical studies and one small retrospective series of 12 patients. Developer-reported bowel-disease trials never published results, and a 2025 pilot involved two people. [13] [14]

How quickly is BPC-157 broken down?

In a 2022 study in rats and dogs, the intact peptide had a half-life of under 30 minutes and was broken down into smaller peptides and amino acids, then cleared through urine and bile. [11]

Is BPC-157 allowed in sport?

No. WADA's Prohibited List names BPC-157 under S0, Non-Approved Substances, banned at all times. [16]

Is BPC-157 approved by Health Canada?

No BPC-157 product is listed in Health Canada's Drug Product Database. In April 2026 Health Canada named BPC-157 in an advisory about unauthorized peptides sold online, and said that "research use only" labels don't exempt products from the rules. The BPC-157 supplied here is for laboratory research. [17]

How should unopened vials be stored?

Keep the vial sealed, dry, protected from light and within any conditions stated in its batch documentation. The handling and storage guide covers this in more detail.

Glossary of Terms

Pentadecapeptide

A peptide made of fifteen amino acids.

Tendon and collagen

Tendons join muscle to bone. Their strength comes from long, tightly packed collagen fibres.

Tendon fibroblast

The slim cell that lives between collagen fibres and makes and maintains them, also called a tenocyte.

Angiogenesis and tip cell

Angiogenesis is the growth of new blood vessels from existing ones. The tip cell leads a new branch, probing ahead with fine projections.

VEGFR2

A receptor on vessel-lining cells that drives new vessel growth when activated.

Nitric oxide

A short-lived signalling molecule that relaxes blood-vessel walls.

Preclinical

Research done in cells or animals, before any testing in people.

HPLC and LAL

HPLC separates a sample to measure purity. The LAL test detects bacterial endotoxin.

References

  1. Sikiric P et al. (1992). The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Acta Physiologica Hungarica 80:89–98. PubMed 1345210
  2. Sikiric P et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal de Physiologie (Paris) 87:313–327. PubMed 8298609
  3. Sikiric P et al. (1994). The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. Life Sciences 54:PL63–PL68. PubMed 7904712
  4. Staresinic M et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research 21:976–983. PubMed 14554208
  5. Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 110:774–780. PubMed 21030672
  6. Chang CH et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 19:19066–19077. PubMed 25415472
  7. Hsieh MJ et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine 95:323–333. PubMed 27847966
  8. Hsieh MJ et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports 10:17078. PubMed 33051481
  9. Gwyer D et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research 377:153–159. PubMed 30915550
  10. Seiwerth S et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology 12:627533. PubMed 34267654
  11. He L et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology 13:1026182. PubMed 36588717
  12. Sikiric P et al. (2012). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry 19:126–132. PubMed 22300085
  13. Vasireddi N et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal 21:485–495. PubMed 40756949
  14. Lee E, Burgess K (2025). Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine 31(5):20–24. PubMed 40131143
  15. ClinicalTrials.gov. NCT02637284: phase I study of PCO-02 (Bepecin, BPC-157) in healthy volunteers. Status unknown; no results posted. clinicaltrials.gov
  16. World Anti-Doping Agency (2026). Prohibited List, S0 Non-Approved Substances. wada-ama.org
  17. Health Canada (April 9, 2026). Think twice before injecting peptides bought online: unauthorized products can seriously harm your health. recalls-rappels.canada.ca
  18. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov
  19. PubChem. BPC 157, CID 9941957. pubchem.ncbi.nlm.nih.gov
  20. U.S. Food and Drug Administration (2026). FDA review of BPC-157 for the Pharmacy Compounding Advisory Committee, July 23–24, 2026. fda.gov
  21. McDermott Will & Schulte (July 2026). Bulk list bound: PCAC backs majority of peptides in two-day public meeting. mcdermottlaw.com